Increasing feasibility and utility of 18F-FDOPA PET for the management of glioma

Bell, Christopher, Dowson, Nicholas, Puttick, Simon, Gal, Yaniv, Thomas, Paul, Fay, Mike, Smith, Jye and Rose, Stephen (2015) Increasing feasibility and utility of 18F-FDOPA PET for the management of glioma. Nuclear Medicine and Biology, 42 10: 788-795. doi:10.1016/j.nucmedbio.2015.06.001

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ365573_OA.pdf Full text (open access) application/pdf 1.30MB 1

Author Bell, Christopher
Dowson, Nicholas
Puttick, Simon
Gal, Yaniv
Thomas, Paul
Fay, Mike
Smith, Jye
Rose, Stephen
Title Increasing feasibility and utility of 18F-FDOPA PET for the management of glioma
Formatted title
Increasing feasibility and utility of 18F-FDOPA PET for the management of glioma
Journal name Nuclear Medicine and Biology   Check publisher's open access policy
ISSN 1872-9614
0969-8051
Publication date 2015-10
Year available 2015
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1016/j.nucmedbio.2015.06.001
Open Access Status File (Author Post-print)
Volume 42
Issue 10
Start page 788
End page 795
Total pages 8
Place of publication Philadelphia, PA, United States
Publisher Elsevier
Collection year 2016
Language eng
Formatted abstract
Introduction:  Despite radical treatment therapies, glioma continues to carry with it a uniformly poor prognosis. Patients diagnosed with WHO Grade IV glioma (glioblastomas; GBM) generally succumb within two years, even those with WHO Grade III anaplastic gliomas and WHO Grade II gliomas carry prognoses of 2–5 and 2 years, respectively. PET imaging with 18F-FDOPA allows in vivo assessment of the metabolism of glioma relative to surrounding tissues. The high sensitivity of 18F-DOPA imaging grants utility for a number of clinical applications.

Methods:  A collection of published work about 18F-FDOPA PET was made and a critical review was discussed and written.

Results:  A number of research papers have been published demonstrating that in conjunction with MRI, 18F-FDOPA PET provides greater sensitivity and specificity than these modalities in detection, grading, prognosis and validation of treatment success in both primary and recurrent gliomas. In further comparisons with 11C-MET, 18F-FLT, 18F-FET and MRI, 18F-FDOPA has shown similar or better efficacy. Recently synthesis cassettes have become available, making 18F-FDOPA more accessible.

Conclusions:  
According to the available data, 18F-FDOPA PET is a viable radiotracer for imaging and treatment planning of gliomas.

Advances in knowledge and implication for patient care:  18F-FDOPA PET appears to be a viable radiopharmaceutical for the diagnosis and treatment planning of gliomas cases, improving on that of MRI and 18F-FDG PET.
Keyword 18F-FDOPA
Dopamine
Glioblastoma
Glioma
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2016 Collection
School of Medicine Publications
Australian Institute for Bioengineering and Nanotechnology Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 3 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 28 Jul 2015, 01:11:04 EST by System User on behalf of School of Medicine